Clinical Trials · NCT05751720
Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 Analogue
- Phase
- Phase 1/Phase 2
- Recruitment status
- Unknown
- Sponsor
- Dr Adnan Agha
- Enrollment
- 30
- Start date
- Oct 2023
- Locations
- 1 site, United Arab Emirates
- Primary endpoint
- change in liver stiffness in terms of kPa